Navigation Links
New drug candidate knocks out resistant form of chronic myeloid leukemia
Date:12/10/2007

PORTLAND, Ore. Oregon Health & Science University Cancer Institute researchers have found a new, experimental drug candidate it to be effective against a highly resistant mutation in chronic myeloid leukemia (CML).

This drug candidate could build on the legacy of Gleevec, which has been the gold standard for treating this leukemia and was developed by Brian Druker, M.D., director of the OHSU Cancer Institute. Despite Gleevecs success, some CML patients develop resistance to Gleevec, often due to mutations that interfere with drug binding. The second-generation drugs Sprycel and Tasigna have been developed as largely successful treatments for Gleevec-resistant patients. However, one mutation, termed T315I, is completely resistant to all three clinical CML drugs and is a frequent cause of relapse.

Now, however, a new drug candidate, SGX393, has been found to inhibit most resistant mutations, including T315I, both in mouse models and in patient cells in laboratory studies. SGX393 was identified by SGX Pharmaceuticals Inc., a biotechnology company focusing on cancer therapeutics.

The OHSU Cancer Institute researchers took this a step further.

Because none of the drugs controlled all of the known mutations, we extended our study to look at using combinations of the drugs, said Christopher Eide, research technician, hematology/medical oncology, OHSU School of Medicine.

Remarkably, we found that the combination of SGX393 with either Sprycel or Tasigna completely suppressed resistant growth. Our findings raise the exciting possibility that inhibitor cocktails may be sufficient to completely pre-empt drug resistance in CML, Eide said.

He is a co-author with OHSU Cancer Institute research scientist Thomas OHare, Ph.D., research specialist, hematology/medical oncology, OHSU School of Medicine.

The study was performed in the laboratory of Michael Deininger, M.D., Ph.D., associate professor of medicine, hematology/medical oncology, OHSU School of Medicine.

What patients should know is that, with the addition of this drug candidate to the currently available set of clinical CML drugs, we may have the therapeutic tools to achieve and maintain even more effective and longer control of their disease, Bumm said.

Gleevec continues to be remarkably successful in the vast majority of patients. However, for those patients who develop resistance, incorporating a targeted T315I inhibitor such as SGX393 into the suite of available CML drugs in the clinic is urgently needed. This is not equivalent to cure, but it could potentially represent an important advance in disease management with CML inhibitor therapy.

SGX Pharmaceuticals, Inc. is targeting submitting an Investigational New Drug application for SGX393 in the first half of 2008.

OHSU has licensed some of the underlying technology used in this research to MolecularMD.


'/>"/>

Contact: Christine Decker
deckerch@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related medicine news :

1. Some Epilepsy Patients Are Good Candidates for Surgery
2. Presidential Candidates Address Health, Financial Security at AARPs Life@50+
3. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
4. U.S. Physicians Question Presidential Candidates
5. Schizophrenia candidate genes affect even healthy individuals
6. Diffusion Pharmaceuticals Announces Results of Phase I Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC) and Completion of a $4.5 Million Private Placement
7. Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
8. Data on Avicenas Drug Candidate HD-02 Presented at the 2007 World Congress on Huntingtons Disease
9. Poll Shows Voters Want Long Term Care Included in Presidential Candidates Healthcare Proposals, Released at 2007 National Long Term Care Symposium
10. 1 in 5 bariatric surgery candidates not psychologically cleared for surgery
11. Albert Einstein Healthcare Network Turns to InterviewDirect to Qualify Job Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/24/2016)... , June 24, 2016  Consumers have ... and regulators/payers have placed more emphasis on patient ... patient support programs in the pharmaceutical industry have ... medications. Consequently, pharmaceutical companies are focusing on becoming ... are providing products and services that improve health. ...
(Date:6/24/2016)... 2016   Bay Area Lyme Foundation , ... Center for Tick Borne Illness , Harvard Medical ... Hacking Medicine, University of California, Berkeley, and the ... five finalists of Lyme Innovation , the ... 100 scientists, clinicians, researchers, entrepreneurs, and investors from ...
Breaking Medicine Technology: